MOUNTAIN VIEW, Calif., May 2, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure ® procedure, the most effective permanent birth control method available, today introduced ...

MOUNTAIN VIEW, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure ® procedure, the most effective non-surgical permanent birth control method available*, ...

Since it was approved to go on the market in 2002, Essure, an implantable permanent contraceptive device, has been plagued by controversy. Thousands of women have filed grievances with the US Food and ...

The FDA also approved an ongoing clinical study plan to further evaluate the benefits and risks of Essure. Essure is still sold in the United States but discontinued in all other countries, including ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov. 4, 2004--Conceptus, Inc. (NASDAQ:CPTS) announced today that the Centers for Medicare and Medicaid Services (CMS) has released the Final Rule for the 2005 ...

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...